BusinessPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile InfectionBy Nasdaq OMXApr 28, 2017, 10:30 PM UTC
